mRNAワクチンと治療の市場レポート：ワクチンタイプ、治療タイプ、ワクチン製造、用途、エンドユーザー、地域別、2024～2032年

世界のmRNAワクチンと治療の市場規模は2023年に577億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて2.53%の成長率（CAGR）を示し、2032年には727億米ドルに達すると予測しています。mRNAベースのワクチンが世界規模で開拓され受け入れられていること、新興・再興感染症に対する迅速かつ適応性の高いソリューションへのニーズが高まっていること、がんや遺伝性疾患の罹患率が増加していることなどが、市場を推進している主要要因の一部です。

mRNAワクチンと治療は、体内の細胞機構を活用して免疫反応を起こします。mRNA（メッセンジャーRNA）は遺伝物質の一種です。COVID-19用に開発されたものを含むワクチンでは、科学者はスパイク・タンパク質として知られる特定のウイルスタンパク質をコードするmRNAの小片を設計します。注入されると、このmRNAは細胞内に入り、このタンパク質を産生するように指示し、免疫反応を引き起こします。治療的アプローチとして、mRNA技術は、単に病気を予防するだけでなく、様々な病気の治療に使用できる可能性があります。適応性が高く、プログラム可能なmRNAの性質は、がんや遺伝性疾患を含む疾患の治療法を迅速かつ柔軟に作り出す方法を提供し、mRNAは治療用タンパク質を産生したり、遺伝的エラーを修正したりするように設計することができるため、これまで治療不可能だった疾患に新たな希望をもたらします。

mRNAワクチンと治療業界は、主にCOVID-19の世界的流行によって牽引されています。これは、mRNAベースのワクチンの開発と世界規模での受容を促し、この技術の有効性と迅速な拡大性を実証しました。これとともに、新興・再興感染症に対する迅速かつ適応性の高い解決策へのニーズが、需要をさらに押し上げています。mRNAワクチンは従来のワクチンよりも迅速に設計できるため、この業界はこのニーズに効果的に対応できる立場にあります。さらに、がんや遺伝性疾患の発生率が高まっており、これらの疾患を治療するmRNA治療の可能性が高まっています。さらに、バイオインフォマティクス、合成生物学、ナノ粒子送達システムの継続的な進歩により、mRNAのより効率的な設計と送達が可能になり、業界の成長に寄与しています。市場を牽引するその他の要因としては、医療インフラの継続的な改善や、主要企業による広範な研究開発活動が挙げられます。

mRNAワクチンと治療の市場動向/促進要因：

慢性疾患と感染症の増加

がん、HIV、ジカ熱などの慢性疾患や感染症の増加に伴い、革新的な治療介入に対するニーズがかなり高まっています。mRNAワクチンや治療法は、体内で治療用タンパク質を産生するよう指示する能力においてユニークであり、幅広い疾患に取り組むための斬新なアプローチを記載しています。これらの治療は分子レベルで病気を対象にできるため、医療の提供方法にパラダイム・シフトをもたらす可能性があります。したがって、こうした技術の市場は、こうした疾患の発生率の上昇や、mRNAベースの治療の潜在的な利点に対する医療提供者、患者、研究者の認識の高まりによって牽引されています。

合成生物学とバイオインフォマティクスの進歩

合成生物学とバイオインフォマティクスの急速な進歩は、mRNAワクチンと治療の開発と改良に役立っています。ゲノミクスに対する理解の向上、遺伝子編集機能の強化、そしてmRNAの構造や挙動を予測するための高度な計算モデルの使用はすべて、mRNA治療のより効果的な設計と送達に貢献しています。これらの進歩はまた、mRNA技術の潜在的用途セグメントを感染症にとどまらず、遺伝性疾患やがんなどへと拡大させています。さらに、合成生物学とバイオインフォマティクスのセグメントでは、最新技術の応用範囲と有効性が拡大しているため、継続的な改良が市場を牽引しています。

個別化医療に対する需要の高まり

個別化医療は、患者個人の遺伝的プロファイルや健康上のニーズに合わせて治療を行うことを目的としています。この医療へのアプローチは、画一的なパラダイムからの大きな脱却を意味し、近年支持を集めています。mRNA技術は、特定の遺伝子プロファイルや特定の疾患変異体を対象として設計できる固有の能力により、この点で大きな可能性を秘めています。mRNAワクチンや治療をカスタマイズするこの可能性は、その治療効果や安全性プロファイルを向上させ、個別化医療の文脈で特に魅力的なものにしています。このことが個別化医療の需要を押し上げています。より多くの医療プロバイダーや患者が個別化医療の利点を認識するようになるにつれ、mRNA技術への需要が高まり、市場に影響を与えています。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 mRNAワクチンと治療の採用

• mRNAワクチンと治療開発の歴史
• 慢性疾患と主要な感染症の発生率と有病率
• mRNAワクチンと治療を用いた予防と治療
  • mRNAの修飾
  • mRNA効率
  • mRNAベースのワクチンのためのアジュバント/刺激剤とキャリア技術
  • mRNAベースのタンパク質と抗体治療のキャリア

第6章 世界のmRNAワクチンと治療市場

• 市場潜在力概要
• 市場の可能性
• COVID-19の影響
• パイプライン中のmRNAワクチン

第7章 市場内訳：ワクチンタイプ別

• 自己増幅型mRNAワクチン
• 従来の非増幅mRNAベースワクチン

第8章 市場内訳：治療タイプ別

• 遺伝子治療
• モノクローナル抗体
• 遺伝子転写
• 細胞療法
• バイオエンジニアリングワクチン
• その他

第9章 市場内訳：ワクチン製造別

• 社内
• アウトソーシング

第10章 市場内訳：用途別

• がん
• 感染症
• 遺伝子編集
• タンパク質の補充

第11章 市場内訳：エンドユーザー別

• 病院とクリニック
• 研究機関
• その他

第12章 市場内訳：地域別

• 北米
  • 市場内訳：国別
• 欧州
  • 市場内訳：国別
• アジア太平洋
  • 市場内訳：国別
• ラテンアメリカ
  • 市場内訳：国別
• 中東・アフリカ
  • 市場内訳：国別

第13章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第14章 バリューチェーン分析

第15章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第16章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Arcturus Therapeutics, Inc.
  • BioNTech SE
  • CureVac AG
  • eTheRNA immunotherapies NV
  • ethris GmbH
  • GlaxoSmithKline PLC
  • Moderna Therapeutics Inc.
  • Translate Bio Inc.
  • Argos Therapeutics, Inc.
  • Sangamo Therapeutics Inc.
  • Pfizer Inc.

List of Figures

• Figure 1: Global: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion US$), 2024-2032
• Figure 2: Global: mRNA Vaccines and Therapeutics Market Potential (Self-amplifying mRNA-Based Vaccines): Value Trends (in Billion US$), 2024-2032
• Figure 3: Global: mRNA Vaccines and Therapeutics Market Potential (Conventional Non-Amplifying mRNA-Based Vaccines): Value Trends (in Billion US$), 2024-2032
• Figure 4: Global: mRNA Vaccines and Therapeutics Market Potential (Gene Therapy): Value Trends (in Billion US$), 2024-2032
• Figure 5: Global: mRNA Vaccines and Therapeutics Market Potential (Monoclonal Antibody): Value Trends (in Billion US$), 2024-2032
• Figure 6: Global: mRNA Vaccines and Therapeutics Market Potential (Gene Transcription): Value Trends (in Billion US$), 2024-2032
• Figure 7: Global: mRNA Vaccines and Therapeutics Market Potential (Cell Therapy): Value Trends (in Billion US$), 2024-2032
• Figure 8: Global: mRNA Vaccines and Therapeutics Market Potential (Bioengineered Vaccine): Value Trends (in Billion US$), 2024-2032
• Figure 9: Global: mRNA Vaccines and Therapeutics Market Potential (Other Treatment Types): Value Trends (in Billion US$), 2024-2032
• Figure 10: Global: mRNA Vaccines and Therapeutics Market Potential (In-House): Value Trends (in Billion US$), 2024-2032
• Figure 11: Global: mRNA Vaccines and Therapeutics Market Potential (Out-Sourced): Value Trends (in Billion US$), 2024-2032
• Figure 12: Global: mRNA Vaccines and Therapeutics Market Potential (Cancer): Value Trends (in Billion US$), 2024-2032
• Figure 13: Global: mRNA Vaccines and Therapeutics Market Potential (Infectious Disease): Value Trends (in Billion US$), 2024-2032
• Figure 14: Global: mRNA Vaccines and Therapeutics Market Potential (Gene Editing): Value Trends (in Billion US$), 2024-2032
• Figure 15: Global: mRNA Vaccines and Therapeutics Market Potential (Protein Replacement): Value Trends (in Billion US$), 2024-2032
• Figure 16: Global: mRNA Vaccines and Therapeutics Market Potential (Hospitals and Clinics): Value Trends (in Billion US$), 2024-2032
• Figure 17: Global: mRNA Vaccines and Therapeutics Market Potential (Research Organizations): Value Trends (in Billion US$), 2024-2032
• Figure 18: Global: mRNA Vaccines and Therapeutics Market Potential (Other End-Users): Value Trends (in Billion US$), 2024-2032
• Figure 19: North America: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion US$), 2024-2032
• Figure 20: North America: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2023
• Figure 21: United States: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 22: Canada: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 23: Europe: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion US$), 2024-2032
• Figure 24: Europe: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2023
• Figure 25: Germany: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 26: United Kingdom: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 27: France: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 28: Italy: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 29: Spain: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 30: Russia: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 31: Others: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 32: Asia Pacific: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion US$), 2024-2032
• Figure 33: Asia Pacific: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2023
• Figure 34: Japan: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 35: China: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 36: Australia: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 37: South Korea: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 38: India: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 39: Indonesia: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 40: Others: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 41: Latin America: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion US$), 2024-2032
• Figure 42: Latin America: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2023
• Figure 43: Brazil: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 44: Mexico: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 45: Others: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Million US$), 2024-2032
• Figure 46: Middle East and Africa: mRNA Vaccines and Therapeutics Market Potential: Value Trends (in Billion US$), 2024-2032
• Figure 47: Middle East and Africa: mRNA Vaccines and Therapeutics Market Potential: Breakup by Country (in %), 2023
• Figure 48: Global: mRNA Vaccines and Therapeutics Industry: SWOT Analysis
• Figure 49: Global: mRNA Vaccines and Therapeutics Industry: Value Chain Analysis
• Figure 50: Global: mRNA Vaccines and Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: mRNA Vaccines and Therapeutics Market Potential: Key Industry Highlights, 2023 and 2032
• Table 2: Global: mRNA Vaccines and Therapeutics Market: List of Pipeline mRNA Vaccines
• Table 3: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Vaccine Type (in Billion US$), 2024-2032
• Table 4: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Treatment Type (in Billion US$), 2024-2032
• Table 5: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Vaccine Manufacturing (in Billion US$), 2024-2032
• Table 6: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Application (in Billion US$), 2024-2032
• Table 7: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by End-User (in Billion US$), 2024-2032
• Table 8: Global: mRNA Vaccines and Therapeutics Market Potential: Breakup by Region (in Billion US$), 2024-2032
• Table 9: Global: mRNA Vaccines and Therapeutics Market: Competitive Structure
• Table 10: Global: mRNA Vaccines and Therapeutics Market: List of Key Players

The global mRNA vaccines and therapeutics market size reached US$ 57.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 72.7 Billion by 2032, exhibiting a growth rate (CAGR) of 2.53% during 2024-2032. The development and acceptance of mRNA-based vaccines on a global scale, the growing need for quick and adaptable solutions for emerging and re-emerging infectious diseases, and the increasing incidence of cancer and genetic diseases are some of the major factors propelling the market.

mRNA vaccines and therapeutics leverages the body's own cellular machinery to generate an immune response. mRNA, or messenger RNA, is a type of genetic material. In the context of vaccines, including those developed for COVID-19, scientists design a small piece of mRNA that codes for a specific viral protein, known as the spike protein. When injected, this mRNA enters cells and instructs them to produce this protein, triggering an immune response. As a therapeutic approach, mRNA technology can be potentially used to treat various diseases, not just prevent them. It's adaptable, programmable nature offers a fast and flexible method for creating treatments for conditions including cancer or genetic disorders, where the mRNA can be designed to produce therapeutic proteins or to correct genetic errors, offering new hope for previously untreatable conditions.

The mRNA vaccines and therapeutics industry is primarily driven by the outbreak of COVID-19 across the globe. This has encouraged the development and acceptance of mRNA-based vaccines on a global scale, demonstrating the effectiveness and rapid scalability of this technology. Along with this, the need for quick and adaptable solutions for emerging and re-emerging infectious diseases further fuels demand. As mRNA vaccines can be designed faster than traditional vaccines, this industry is positioned to address this need effectively. Additionally, the growing incidence of cancer and genetic diseases and the potential of mRNA therapeutics to treat these conditions. In addition, continuous advancements in bioinformatics, synthetic biology, and nanoparticle delivery systems are enabling more efficient design and delivery of mRNA, contributing to the industry's growth. Some of the other factors driving the market include continual improvements in healthcare infrastructure and extensive research and development activities conducted by key players.

mRNA Vaccines and Therapeutics Market Trends/Drivers:

Growing Incidence of Chronic and Infectious Diseases

With the rise of chronic and infectious diseases such as cancer, HIV, and Zika, there has been a considerable increase in the need for innovative therapeutic interventions. mRNA vaccines and therapies are unique in their ability to instruct the body to produce its own therapeutic proteins, offering a novel approach to tackling a wide range of diseases. As these treatments can target diseases at a molecular level, they represent a potential paradigm shift in how healthcare is provided. The market for these technologies is thus driven by the rising incidence of these diseases, as well as the increasing recognition among healthcare providers, patients, and researchers of the potential benefits of mRNA-based treatments.

Advancements in Synthetic Biology and Bioinformatics

The rapid pace of advancements in synthetic biology and bioinformatics has been instrumental in the development and refinement of mRNA vaccines and therapeutics. An improved understanding of genomics, enhanced capabilities in gene editing, and the use of sophisticated computational models to predict mRNA structure and behavior have all contributed to the more effective design and delivery of mRNA therapies. These advancements also expand the potential applications of mRNA technologies beyond infectious diseases to include genetic disorders and cancers, among others. The market is further driven by continual improvements in the fields of synthetic biology and bioinformatics due to the increasing scope and efficacy of modern technologies.

Rising Demand for Personalized Medicine

Personalized medicine aims to tailor treatments to the individual patient's unique genetic profile and health needs. This approach to healthcare represents a significant departure from the one-size-fits-all paradigm and has been gaining traction in recent years. mRNA technologies hold significant promise in this regard due to their inherent ability to be designed for specific genetic profiles or to target specific disease variants. This potential to customize mRNA vaccines and treatments is improving their therapeutic efficacy and safety profile, making them particularly attractive in the context of personalized medicine. This is propelling the demand for personalized medicine. As more healthcare providers and patients become aware of the benefits of personalized medicine, the demand for mRNA technologies is escalates, thereby impacting the market.

mRNA Vaccines and Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global mRNA vaccines and therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on vaccine type, treatment type, vaccine manufacturing, application, and end-user.

Breakup by Vaccine Type:

Self-amplifying mRNA-Based Vaccines

Conventional Non-Amplifying mRNA-Based Vaccines

Conventional non-amplifying mRNA-based vaccines dominate the market

The report has provided a detailed breakup and analysis of the mRNA vaccines and therapeutics market based on the vaccine type. This includes self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines. According to the report, conventional non-amplifying mRNA-based vaccines represented the largest segment.

The growing global health concerns about emerging infectious diseases and the need for quick vaccine development are majorly driving the market segment. These vaccines can be quickly produced and modified, making them ideally suited for combatting rapidly mutating diseases such as influenza and COVID-19. Additionally, the recent success of mRNA vaccines is leading to an increased acceptance and trust in this technology, influencing the market demand. Along with this, the rising prevalence of cancer, and the potential of mRNA vaccines for cancer treatment, also act as a significant market driver. Moreover, continual technological advancements and significant investments in research and development of mRNA technology play a crucial role in shaping the market.

The market for conventional non-amplifying mRNA-based vaccines has also seen rapid growth due to the acceptance and adoption of mRNA technology, demonstrating its ability to rapidly develop effective vaccines against novel pathogens. This has led to increased investment in mRNA research and development, and growing confidence in its potential. Additionally, the relatively quick and cost-effective production process of mRNA vaccines, as well as their versatility for targeting a variety of diseases. As diseases evolve and new pathogens emerge, the capacity for rapid design modifications is becoming an increasingly important market driver. Besides, there is a rising focus on personalized medicine, and mRNA vaccines have the potential to be tailored to individual patient needs, such as for cancer immunotherapy, providing another strong growth driver in the market.

Breakup by Treatment Type:

Bioengineered Vaccine

Gene Therapy

Gene Transcription

Cell Therapy

Monoclonal Antibody

Others

Bioengineered vaccine dominate the market

A detailed breakup and analysis of the mRNA vaccines and therapeutics market based on the treatment type has also been provided in the report. This includes gene therapy, monoclonal antibody, gene transcription, cell therapy, bioengineered vaccine, and others. According to the report, bioengineered vaccine accounted for the largest market share.

Bioengineered vaccines' ability to be quickly designed and mass-produced in response to new viral threats positions them as a vital tool in global health security, fostering increased investment and demand. In addition, the ongoing research exploring the potential of mRNA therapeutics beyond vaccines, such as in cancer immunotherapy and genetic diseases, broadens the industry's scope. Moreover, policy support from governments and collaborations between pharma-biotech companies contribute to the acceleration of mRNA-based research, development, and commercialization.

On the other hand, the broad therapeutic potential of gene therapies for a wide array of genetic, oncologic, and chronic diseases are expected to augment the growth of the segment. Technological advancements in gene editing tools, including CRISPR-Cas9, have facilitated the development and refinement of mRNA-based gene therapies. The growing prevalence of genetic disorders and the urgent need for effective treatments have also spurred interest and investment in this sector. Besides this, favorable government policies, increased healthcare expenditure, and strategic collaborations among biotech and pharmaceutical companies accelerate this industry's growth.

The market for gene transcription in the mRNA vaccines and therapeutics industry is further fueled by the creation of innovative treatment modalities for various diseases. Along with this, advancements in genomics and transcriptomics technology are enhancing our ability to manipulate and understand gene transcription, further driving the market. In addition, the rise in the prevalence of diseases, including cancer, where abnormal gene transcription plays a key role, necessitates continued investment and exploration in this field.

Breakup by Vaccine Manufacturing:

In-House

Out-Sourced

In-house manufacturing dominate the mRNA vaccines and therapeutics market

The report has provided a detailed breakup and analysis of the mRNA vaccines and therapeutics market based on vaccine manufacturing. This includes in-house and out-sourced. According to the report, in-house represented the largest segment.

The potential of mRNA technologies to treat a broad array of diseases beyond infectious diseases, including cancer, is acting as a catalyst for companies to invest in their own manufacturing capabilities. The need for supply chain security and independence, the desire to control quality standards, and the potential cost savings over time through economies of scale also play a significant role in driving the move towards in-house manufacturing. In addition, advancements in manufacturing technologies and processes are making in-house production more feasible and cost-effective, even for smaller biotech companies.

On the contrary, the market drivers for outsourced manufacturing in the mRNA vaccines and therapeutics industry are predominantly shaped by the rapid advancement in biotechnologies, coupled with the global urgency to respond to emerging health crises. One key market driver is the need for speed and scalability in vaccine production to meet global demand, particularly in times of health crises. Outsourced manufacturing allows for quicker ramp-up of production capacity. Additionally, the complexity and specialized requirements of mRNA vaccine production, including high-precision cold-chain logistics and proprietary lipid nanoparticle technology, demand a level of expertise that not all pharmaceutical companies possess. This drives the demand for specialized contract manufacturing organizations (CMOs) that have the necessary technology and know-how.

Breakup by Application:

Cancer

Infectious Disease

Gene Editing

Protein Replacement

Infectious disease dominate the market

A detailed breakup and analysis of the mRNA vaccines and therapeutics market based on the application has also been provided in the report. This includes cancer, infectious disease, gene editing, and protein replacement. According to the report, infectious disease accounted for the largest market share.

The mRNA vaccines and therapeutics industry for infectious diseases is majorly influenced by the unprecedented global demand for effective vaccines to combat emergent infectious diseases. This is largely due to the unique ability of mRNA vaccines to be rapidly designed and produced in response to new viral threats. Furthermore, the relatively high efficacy and favorable safety profile of approved mRNA vaccines, such as those from Moderna and Pfizer-BioNTech, is supporting the confidence in this innovative technology.

On the other hand, the cancer application is driven due to the growing global burden of cancer, with increasing incidence rates across various age groups. Along with this, the growing need for effective treatments is propelling research and innovation in mRNA therapeutics. mRNA vaccines have gained substantial attention due to their success in tackling infectious diseases. Technological advancements in bioinformatics and nanotechnology enable the fine-tuning of mRNA vaccines for cancer-specific antigens, further driving this market.

Breakup by End-User:

Hospitals and Clinics

Research Organizations

Others

Hospitals and clinics dominate the market

The report has provided a detailed breakup and analysis of the mRNA vaccines and therapeutics market based on end-user. This includes hospitals and clinics, research organizations, and others. According to the report, hospitals and clinics represented the largest segment.

Numerous factors for hospitals and clinics end-user in the mRNA vaccines and therapeutics industry includes the necessity for efficient, fast-developing vaccines to combat existing and emerging infectious diseases, which was underscored by the successful implementation of mRNA technology. Along with this, the increasing prevalence of cancer and genetic diseases also raises the demand, as mRNA therapeutics provide innovative, personalized treatment approaches. Additionally, the growing awareness and acceptance of mRNA vaccines and therapeutics among medical practitioners and patients also contributes to this growth.

The market drivers for research organizations in the mRNA vaccines and therapeutics industry are largely defined by the growing prevalence of infectious diseases and cancers, increased investment in R&D, and rapid advancements in biotechnology. Additionally, the shifting preference towards personalized medicine, with mRNA therapeutics playing a critical role in this evolution. Governmental support and funding for mRNA research, coupled with a strong pipeline of mRNA-based therapeutics and vaccines in clinical trials, are also significant market drivers.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Europe exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, United Kingdom, France, Italy, Spain, Russia and others ); Asia Pacific (Japan, China, Australia, South Korea, India, Indonesia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The mRNA vaccines and therapeutics industry in Europe is driven by ongoing investment in research and development fuels the expansion of the mRNA portfolio beyond vaccines into potential cures for cancer, genetic diseases, and other chronic conditions, further propelling the market growth. The presence of seamless approval processes, implemented during the pandemic, also act as a catalyst, facilitating quicker route-to-market and uptake for novel mRNA products. Moreover, the strong presence of key industry players in the region, underpin the robust growth of the mRNA vaccines and therapeutics market.

On the contrary, Asia Pacific is estimated to expand further in this domain due to the rising prevalence of infectious diseases, and the increased awareness of the need for preventative measures. Technological advancements are also key, as growing research and development capabilities in countries, such as China and India are accelerating the pace of innovative mRNA therapeutics. Additionally, the region's large population base provides a massive potential demand for these vaccines.

Competitive Landscape:

The global mRNA vaccines and therapeutics market is experiencing significant growth due to the increasing investments in research and development (R&D) to create more effective vaccines and therapeutics, as well as to expand the use of mRNA technology beyond vaccines to a broader range of therapeutic applications, including cancer treatment, cardiovascular diseases, and genetic disorders. Along with this, companies are forging partnerships and collaborations with academic institutions, biotech firms, and other pharmaceutical companies to accelerate the development of mRNA vaccines and therapeutics. This approach helps to pool resources, share knowledge, and diversify risk. In addition, companies are working closely with regulatory bodies across the globe to ensure their products meet safety and efficacy requirements. They are conducting extensive clinical trials and are in constant communication with authorities to secure approvals for their products. Furthermore, companies are also investing in efforts to educate the public about the safety and efficacy of mRNA vaccines, to overcome vaccine hesitancy and misinformation.

The report has provided a comprehensive analysis of the competitive landscape in the global mRNA vaccines and therapeutics market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Arcturus Therapeutics Inc.

BioNTech SE

CureVac AG

eTheRNA immunotherapies NV

ethris GmbH

GlaxoSmithKline PLC

Moderna Therapeutics Inc.

Translate Bio Inc.

Argos Therapeutics, Inc.

Sangamo Therapeutics Inc.

Pfizer Inc.

Recent Developments:

In January 2023, Arcturus Therapeutics Inc. stated that the clinical trial proposal for the cystic fibrosis drug arct-032 gained clearance to move forward with first-in-human research.

In October 2022, Moderna Therapeutics Inc. revealed that it has acquired an emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its bivalent COVID-19 booster vaccine, mRNA-1273.222, which targets the BA.4/BA.5 omicron in children and adolescents between the ages of 6 and 17.

In June 2022, CureVac AG announced the purchase of private business Frame Cancer Therapeutics (Frame), a leader in sophisticated genomics and bioinformatics.

Key Questions Answered in This Report

• 1. What was the size of the global mRNA vaccines and therapeutics market in 2023?
• 2. What is the expected growth rate of the global mRNA vaccines and therapeutics market during 2024-2032?
• 3. What are the key factors driving the global mRNA vaccines and therapeutics market?
• 4. What has been the impact of COVID-19 on the global mRNA vaccines and therapeutics market?
• 5. What is the breakup of the global mRNA vaccines and therapeutics market based on the vaccine type?
• 6. What is the breakup of the global mRNA vaccines and therapeutics market based on the treatment type?
• 7. What is the breakup of the global mRNA vaccines and therapeutics market based on vaccine manufacturing?
• 8. What is the breakup of the global mRNA vaccines and therapeutics market based on the application?
• 9. What is the breakup of the global mRNA vaccines and therapeutics market based on the end-user?
• 10. What are the key regions in the global mRNA vaccines and therapeutics market?
• 11. Who are the key players/companies in the global mRNA vaccines and therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Introduction to mRNA Vaccines and Therapeutics

• 5.1 History of mRNA Vaccines and Therapeutics Development
• 5.2 Incidence and Prevalence of Chronic Diseases and Major Infectious Diseases
• 5.3 Prevention and Treatment Using mRNA Vaccines and Therapeutics
  • 5.3.1 mRNA Modifications
  • 5.3.2 mRNA Efficiencies
  • 5.3.3 Adjuvant/Stimulant and Carrier Technologies for mRNA-Based Vaccines
  • 5.3.4 Carriers for mRNA-Based Protein and Antibody Therapeutics

6 Global mRNA Vaccines and Therapeutics Market

• 6.1 Market Potential Overview
• 6.2 Market Potential
• 6.3 Impact of COVID-19
• 6.4 mRNA Vaccines in Pipeline

7 Market Breakup by Vaccine Type

• 7.1 Self-amplifying mRNA-Based Vaccines
• 7.2 Conventional Non-Amplifying mRNA-Based Vaccines

8 Market Breakup by Treatment Type

• 8.1 Gene Therapy
• 8.2 Monoclonal Antibody
• 8.3 Gene Transcription
• 8.4 Cell Therapy
• 8.5 Bioengineered Vaccine
• 8.6 Others

9 Market Breakup by Vaccine Manufacturing

• 9.1 In-House
• 9.2 Out-Sourced

10 Market Breakup by Application

• 10.1 Cancer
• 10.2 Infectious Disease
• 10.3 Gene Editing
• 10.4 Protein Replacement

11 Market Breakup by End-User

• 11.1 Hospitals and Clinics
• 11.2 Research Organizations
• 11.3 Others

12 Market Breakup by Region

• 12.1 North America
  • 12.1.1 Market Breakup by Country
    • 12.1.1.1 United States
    • 12.1.1.2 Canada
• 12.2 Europe
  • 12.2.1 Market Breakup by Country
    • 12.2.1.1 Germany
    • 12.2.1.2 United Kingdom
    • 12.2.1.3 France
    • 12.2.1.4 Italy
    • 12.2.1.5 Spain
    • 12.2.1.6 Russia
    • 12.2.1.7 Others
• 12.3 Asia Pacific
  • 12.3.1 Market Breakup by Country
    • 12.3.1.1 Japan
    • 12.3.1.2 China
    • 12.3.1.3 Australia
    • 12.3.1.4 South Korea
    • 12.3.1.5 India
    • 12.3.1.6 Indonesia
    • 12.3.1.7 Others
• 12.4 Latin America
  • 12.4.1 Market Breakup by Country
    • 12.4.1.1 Brazil
    • 12.4.1.2 Mexico
    • 12.4.1.3 Others
• 12.5 Middle East and Africa
  • 12.5.1 Market Breakup by Country

13 SWOT Analysis

• 13.1 Overview
• 13.2 Strengths
• 13.3 Weaknesses
• 13.4 Opportunities
• 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

• 15.1 Overview
• 15.2 Bargaining Power of Buyers
• 15.3 Bargaining Power of Suppliers
• 15.4 Degree of Competition
• 15.5 Threat of New Entrants
• 15.6 Threat of Substitutes

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Arcturus Therapeutics, Inc.
  • 16.3.2 BioNTech SE
  • 16.3.3 CureVac AG
  • 16.3.4 eTheRNA immunotherapies NV
  • 16.3.5 ethris GmbH
  • 16.3.6 GlaxoSmithKline PLC
  • 16.3.7 Moderna Therapeutics Inc.
  • 16.3.8 Translate Bio Inc.
  • 16.3.9 Argos Therapeutics, Inc.
  • 16.3.10 Sangamo Therapeutics Inc.
  • 16.3.11 Pfizer Inc.